Imatinib (IM), one of tyrosine kinase inhibitors (TKIs), specifically inhibiting BCR-ABL fusion protein and triggering apoptosis and differentiation of CML cells, is used as first-line treatment for CML. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.